<DOC>
	<DOCNO>NCT00857233</DOCNO>
	<brief_summary>The primary objective study examine safety tolerability memantine outpatient moderate severe Alzheimer 's Disease .</brief_summary>
	<brief_title>Safety Tolerability Memantine Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description>Memantine moderate affinity , uncompetitive N-methyl-D-aspartate ( NMDA ) receptor antagonist . Pre-clinical study demonstrate memantine decrease neuronal toxicity associate excessive glutamate release calcium overload neuron . Results clinical trial patient moderate severe Alzheimer 's Disease ( AD ) demonstrate memantine 's efficacy safety show positive treatment effect cognitive , global functional decline . The purpose 24-week open-label extension study collect additional long-term safety tolerability data memantine patient complete lead-in double-blind placebo-controlled Study 10158 . In agreement Health Canada study prematurely terminate due recruitment difficulty lead-in Study 10158 . Patients ongoing study decision terminate take allow complete .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Ambulatory outpatient moderate severe dementia Alzheimer 's type complete 24week Study 10158 knowledgeable reliable caregiver accompany patient clinic visit course study . Diseases/medication judge investigator could interfere assessment safety , tolerability efficacy .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>